Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy ...

Arbutus (ABUS) looks stronger after Moderna validates its LNP patents, with imdusiran showing durable viral control and a ...

The product targets patients on long-term NSAID therapy who face elevated risk of gastrointestinal complications.

Sam Neill's battle with rare blood cancer AITL highlighted its symptoms, diagnosis, CAR-T therapy advances, and the ...

UCSF is rolling out an aggressive new play in the fight against Alzheimer’s, launching a nationwide clinical trial that pairs ...

Fluoxetine, cognitive behavioral therapy, and combined therapy offer similar symptom reduction among youths with anxiety disorders.

Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer ...

A Look at Heated Compression Foot Massagers and Where the EMSense Triple Therapy Device Sits in the Wider Conversation About At-Home Foot Comfort and Circulation Support An overview of the growing ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...

UCSF has launched the Alzheimer's Tau Platform (ATP) trial, the first large-scale clinical trial testing combination therapies that target both amyloid plaques and tau tangles simultaneously.

Adding venetoclax to hypomethylating agents increased composite remission but did not improve overall survival in HR-MDS.